Definium Therapeutics, Inc. (DFTX)
22.84
-0.58
(-2.48%)
USD |
NASDAQ |
May 07, 13:24
Definium Therapeutics Cash from Investing (Quarterly) : 37.53M for Dec. 31, 2025
Cash from Investing (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Investing (Quarterly) Benchmarks
| Atai Beckley, Inc. | -40.59M |
| Plus Therapeutics, Inc. | -1.077M |
| Viridian Therapeutics, Inc. | 77.26M |
| Nutriband, Inc. | 0.00 |
| Immunovant, Inc. | 0.00 |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -41.89M |
| Cash from Financing (Quarterly) | 246.10M |
| Free Cash Flow | -131.84M |
| Free Cash Flow Per Share (Quarterly) | -0.4241 |
| Free Cash Flow to Equity (Quarterly) | -42.09M |
| Free Cash Flow to Firm (Quarterly) | -40.62M |
| Free Cash Flow Yield | -6.50% |